Professional Documents
Culture Documents
J11-028.doc
Introduction:
Tamoxifen, a non-steroidal anti-estrogen is now widely used and has
led to an increase in both disease-free and overall survival of women after
primary surgery. A complicating factor is the relapse in breast cancer
patients during tamoxifen therapy and in this subset of patients treatment is
only palliative and recurrent breast cancer is incurable. TAM therapy is
found to cause hypertriglyceridemia by reduced activity of lipolytic
enzymes on triglycerides, and thereby increasing the risk of cardiovascular
disease. Angiogenesis promotes local tumour progression and invasion and
enables tumour cell dissemination and metastasis formation. Our study has
found that co-administration of CoenzymeQ10 (100 mg) along with
tamoxifen (10 mg, twice a day) to breast cancer patients reduced the level of
angiogenesis markers and lipid levels.
1/1
Diagnostics, India). Plasma free cholesterol, Plasma FFA and Plasma
Phospholipids were estimated by standard laboratory protocol. The
difference between total cholesterol and free cholesterol is the ester
cholesterol content of plasma. Plasma HDL was determined by precipitating
VLDL and LDL with heparin and manganese at pH 5.04 (Agappe,
Diagnostics, India). The HDL remaining in the supernatant was determined
enzymatically as described for the measurement of the total cholesterol.
Concentration of the plasma LDL was calculated by the standard
Friedewald equation.